InVivo Therapeutics Holdings Corp (NVIVQ)

[DDobserver]

You and I must not be looking at the same company facts. Lets see you claim this is a great buying opportunity.

The FDA has thrown the studies back at least a year. Revenues will not be until 2018-2019 at a minimum. The gel study is many months out. The cervical study cannot start until the current study is proven. The Chief Medical Officer is retiring. The executive staff is not buying into the company but are happy to take handsome salaries, benefits, and stock options. Limited updates from the executive staff as to the progress of the study and patients. Couple all of this with the unknown of the election. Finally, the Fed is signalling they will raise rates which will effect the global market. The intrinsic value of this company is .80 cents per share. Not the overpriced absurd 4-5 dollars per share it currently is at.